{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:31:26Z","timestamp":1793878286856,"version":"4.7.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U01DA038876"],"award-info":[{"award-number":["U01DA038876"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA047711"],"award-info":[{"award-number":["UG3DA047711"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.neuropharm.2021.108653","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T11:25:50Z","timestamp":1623410750000},"page":"108653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder"],"prefix":"10.1016","volume":"195","author":[{"given":"M.D.","family":"Raleigh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Baruffaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Saykao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Winston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"LeSage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.R.","family":"Pentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pravetoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2021.108653_bib1","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1097\/00001756-200110080-00017","article-title":"Differential in vivo internalization of MOR-1 and MOR-1C by morphine","volume":"12","author":"Abbadie","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2021.108653_bib2","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1016\/j.vaccine.2006.01.047","article-title":"A novel bivalent morphine\/heroin vaccine that prevents relapse to heroin addiction in rodents","volume":"24","author":"Anton","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.neuropharm.2021.108653_bib3","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1021\/acs.molpharmaceut.8b00592","article-title":"Preclinical efficacy and characterization of candidate vaccines for treatment of opioid use disorders using clinically viable carrier proteins","volume":"15","author":"Baruffaldi","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.neuropharm.2021.108653_bib4","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1021\/acs.molpharmaceut.8b01296","article-title":"Formulation and characterization of conjugate vaccines to reduce opioid use disorders suitable for pharmaceutical manufacturing and clinical evaluation","volume":"16","author":"Baruffaldi","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.neuropharm.2021.108653_bib5","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/0024-3205(90)90604-P","article-title":"Antibodies to morphine in workers exposed to opiates at a narcotics manufacturing facility and evidence for similar antibodies in heroin abusers","volume":"47","author":"Biagini","year":"1990","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2021.108653_bib6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/252708a0","article-title":"Changes in heroin self-administration by a rhesus monkey after morphine immunisation","volume":"252","author":"Bonese","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2021.108653_bib7","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/anie.201511654","article-title":"Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs","volume":"55","author":"Bremer","year":"2016","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.neuropharm.2021.108653_bib8","series-title":"Increase in Fatal Drug Overdoses across the United States Driven by Synthetic Opioids before and during the COVID-19 Pandemic","author":"CDC","year":"2020"},{"key":"10.1016\/j.neuropharm.2021.108653_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41541-020-00247-7","article-title":"Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders","volume":"5","author":"Crouse","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.neuropharm.2021.108653_bib10","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1073\/pnas.73.10.3671","article-title":"Molecular determinants of immunogenicity: the immuno model of immune response","volume":"73","author":"Dintzis","year":"1976","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2021.108653_bib11","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ajem.2014.05.051","article-title":"Nebulized fentanyl vs intravenous morphine for ED patients with acute limb pain: a randomized clinical trial","volume":"32","author":"Farahmand","year":"2014","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.neuropharm.2021.108653_bib12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0024-3205(93)90656-N","article-title":"Immune response to opiates: new findings in heroin addicts investigated by means of an original enzyme immunoassay and morphine determination in hair","volume":"53","author":"Gamaleya","year":"1993","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2021.108653_bib13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2010.317","article-title":"Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic","volume":"89","author":"Hatsukami","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2021.108653_bib14","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clpt.2005.08.007","article-title":"Safety and immunogenicity of a nicotine conjugate vaccine in current smokers","volume":"78","author":"Hatsukami","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2021.108653_bib15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jeab.7","article-title":"Behavioral economics and empirical public policy","volume":"99","author":"Hursh","year":"2013","journal-title":"J. Exp. Anal. Behav."},{"key":"10.1016\/j.neuropharm.2021.108653_bib16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1037\/0033-295X.115.1.186","article-title":"Economic demand and essential value","volume":"115","author":"Hursh","year":"2008","journal-title":"Psychol. Rev."},{"key":"10.1016\/j.neuropharm.2021.108653_bib17","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acschemneuro.8b00079","article-title":"Efficacious vaccine against heroin contaminated with fentanyl","volume":"9","author":"Hwang","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108653_bib18","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1016\/j.vaccine.2019.05.061","article-title":"Heroin vaccine: using titer, affinity, and antinociception as metrics when examining sex and strain differences","volume":"37","author":"Hwang","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.neuropharm.2021.108653_bib19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.mce.2013.08.021","article-title":"Structural biology of glycoprotein hormones and their receptors: insights to signaling","volume":"382","author":"Jiang","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.neuropharm.2021.108653_bib20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/cr.2007.75","article-title":"Metabolic enzymes link morphine withdrawal with metabolic disorder","volume":"17","author":"Jiang","year":"2007","journal-title":"Cell Res."},{"key":"10.1016\/j.neuropharm.2021.108653_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/FBP.0000000000000218","article-title":"Dose and elasticity of demand for self-administered cocaine in rats","volume":"27","author":"Kearns","year":"2016","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108653_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1021\/acschembio.6b00977","article-title":"An advance in prescription opioid vaccines: overdose mortality reduction and extraordinary alteration of drug half-life","volume":"12","author":"Kimishima","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.neuropharm.2021.108653_bib23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1521-0391.2014.12152.x","article-title":"Attenuation of cocaine-induced locomotor activity in male and female mice by active immunization","volume":"23","author":"Kosten","year":"2014","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.neuropharm.2021.108653_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pnpbp.2013.05.012","article-title":"A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats","volume":"45","author":"Kosten","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2021.108653_bib25","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0264-410X(01)00425-X","article-title":"Human therapeutic cocaine vaccine: safety and immunogenicity","volume":"20","author":"Kosten","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.neuropharm.2021.108653_bib26","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1038\/s41598-018-23777-6","article-title":"Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose","volume":"8","author":"Laudenbach","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2021.108653_bib27","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.4049\/jimmunol.1500385","article-title":"The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse","volume":"194","author":"Laudenbach","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.neuropharm.2021.108653_bib28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00213-003-1539-2","article-title":"Effects of continuous nicotine infusion on nicotine self-administration in rats: relationship between continuously infused and self-administered nicotine doses and serum concentrations","volume":"170","author":"LeSage","year":"2003","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108653_bib29","article-title":"A conjugate vaccine attenuates morphine- and heroin-induced behavior in rats","volume":"18","author":"Li","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2021.108653_bib30","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/eji.200526285","article-title":"A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity","volume":"35","author":"Maurer","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.neuropharm.2021.108653_bib31","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.neuropharm.2018.06.026","article-title":"Prophylactic vaccination protects against the development of oxycodone self-administration","volume":"138","author":"Nguyen","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108653_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.111.189506","article-title":"An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia","volume":"341","author":"Pravetoni","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108653_bib33","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/jm3013745","article-title":"Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens","volume":"56","author":"Pravetoni","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108653_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101807","article-title":"Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats","volume":"9","author":"Pravetoni","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2021.108653_bib35","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1016\/j.vaccine.2012.04.101","article-title":"Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats","volume":"30","author":"Pravetoni","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.neuropharm.2021.108653_bib36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/jpet.118.253674","article-title":"A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats","volume":"368","author":"Raleigh","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108653_bib37","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.117.247049","article-title":"Opioid dose- and route-dependent efficacy of oxycodone and heroin vaccines in rats","volume":"365","author":"Raleigh","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108653_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115696","article-title":"Pharmacokinetic correlates of the effects of a heroin vaccine on heroin self-administration in rats","volume":"9","author":"Raleigh","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2021.108653_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184876","article-title":"Safety and efficacy of an oxycodone vaccine: addressing some of the unique considerations posed by opioid abuse","volume":"12","author":"Raleigh","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2021.108653_bib40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.112.201194","article-title":"Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats","volume":"344","author":"Raleigh","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108653_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.21106\/ijma.284","article-title":"Opioid epidemic in the United States: empirical trends, and A literature review of social determinants and epidemiological, pain management, and treatment patterns","volume":"8","author":"Singh","year":"2019","journal-title":"Int J MCH AIDS"},{"key":"10.1016\/j.neuropharm.2021.108653_bib42","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1021\/jm200461m","article-title":"A vaccine strategy that induces protective immunity against heroin","volume":"54","author":"Stowe","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108653_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107730","article-title":"Vaccine blunts fentanyl potency in male rhesus monkeys","volume":"158","author":"Tenney","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108653_bib44","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/253565a0","article-title":"Prevention of the effects of fentanyl by immunological means","volume":"253","author":"Torten","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2021.108653_bib45","series-title":"World Drug Report 2020","author":"UNODC","year":"2020"},{"key":"10.1016\/j.neuropharm.2021.108653_bib46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5847\/wjem.j.1920-8642.2019.01.004","article-title":"Comparison between intravenous morphine versus fentanyl in acute pain relief in drug abusers with acute limb traumatic injury","volume":"10","author":"Vahedi","year":"2019","journal-title":"World J Emerg Med"},{"key":"10.1016\/j.neuropharm.2021.108653_bib47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs","volume":"59","author":"Volpe","year":"2011","journal-title":"Regul. Toxicol. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821002082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821002082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:13:14Z","timestamp":1758438794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821002082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":47,"alternative-id":["S0028390821002082"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108653","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108653"}}